170 related articles for article (PubMed ID: 32988920)
1. Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
Chen HJ; Tu CY; Hsia TC; Fang HY; Chen CH; Chen SC; Li CH; Liao YM; Hsieh CY; Lein MY; Liang JA; Chien CR
Anticancer Res; 2020 Oct; 40(10):5895-5899. PubMed ID: 32988920
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495
[TBL] [Abstract][Full Text] [Related]
5. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
6. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
7. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
[TBL] [Abstract][Full Text] [Related]
9. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
10. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
11. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
12. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
13. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
14. Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer.
Filippi AR; Guerrera F; Badellino S; Ceccarelli M; Castiglione A; Guarneri A; Spadi R; Racca P; Ciccone G; Ricardi U; Ruffini E
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):505-12. PubMed ID: 26899780
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
16. Radiosurgery for brain metastases from primary lung carcinoma.
Hoffman R; Sneed PK; McDermott MW; Chang S; Lamborn KR; Park E; Wara WM; Larson DA
Cancer J; 2001; 7(2):121-31. PubMed ID: 11324765
[TBL] [Abstract][Full Text] [Related]
17. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes.
Ursino S; Montrone S; Cantarella M; Menghini V; Matteucci F; Mazzotti V; Fiorica F; Fedele D; Erba P; Morganti R; Fabrini MG; Caramella D
Tumori; 2016; 102(1):59-64. PubMed ID: 26439149
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
Chin AL; Kumar KA; Guo HH; Maxim PG; Wakelee H; Neal JW; Diehn M; Loo BW; Gensheimer MF
Clin Lung Cancer; 2018 Sep; 19(5):e581-e588. PubMed ID: 29759331
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
